Short Interest in Kiromic BioPharma, Inc. (NASDAQ:KRBP) Expands By 110.9%

Kiromic BioPharma, Inc. (NASDAQ:KRBPGet Rating) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 267,900 shares, a growth of 110.9% from the February 13th total of 127,000 shares. Based on an average trading volume of 1,860,000 shares, the days-to-cover ratio is currently 0.1 days.

Kiromic BioPharma Price Performance

Shares of Kiromic BioPharma stock opened at $0.16 on Monday. Kiromic BioPharma has a 1 year low of $0.14 and a 1 year high of $0.90. The stock has a market cap of $3.24 million, a price-to-earnings ratio of -0.16 and a beta of 0.22. The firm’s 50-day moving average is $0.19 and its two-hundred day moving average is $0.26.

Hedge Funds Weigh In On Kiromic BioPharma

An institutional investor recently bought a new position in Kiromic BioPharma stock. Renaissance Technologies LLC purchased a new position in shares of Kiromic BioPharma, Inc. (NASDAQ:KRBPGet Rating) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 56,111 shares of the company’s stock, valued at approximately $48,000. Renaissance Technologies LLC owned approximately 0.36% of Kiromic BioPharma at the end of the most recent quarter. Institutional investors and hedge funds own 12.62% of the company’s stock.

Kiromic BioPharma Company Profile

(Get Rating)

Kiromic BioPharma, Inc, an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1.

Featured Stories

Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with's FREE daily email newsletter.